Vitamin D, Cancer Risk, and Mortality

Area of Science:

• Oncology
• Endocrinology
• Molecular Biology

Background:

• 1,25-dihydroxyvitamin D exhibits antiproliferative effects, influencing cell differentiation, proliferation, invasion, angiogenesis, and metastasis.
• Low serum 25(OH)D levels correlate with colorectal cancer and overall mortality, though cancer mortality associations are inconsistent.
• Vitamin D's effects are mediated by the vitamin D receptor (VDR) and vitamin D-binding protein (DBP), with conflicting data on their roles in malignancies.

Purpose of the Study:

• To review the evidence on vitamin D's role in cancer prevention and treatment.
• To investigate the association between vitamin D status, supplementation, and cancer outcomes.
• To identify gaps in current research and the need for further clinical trials.

Main Methods:

• Review of meta-analyses and published trials on vitamin D supplementation and cancer risk, prognosis, and mortality.
• Examination of epidemiological and preclinical studies on vitamin D's anticancer properties.
• Analysis of genetic polymorphisms in the GC gene (encoding DBP) and their association with cancer development.

Main Results:

• Vitamin D supplementation is associated with reduced overall mortality in healthy subjects, but evidence for cancer risk and mortality is less clear.
• Low vitamin D status shows significant associations with overall mortality and cancer outcomes, more so than cancer incidence.
• Conflicting data exist regarding the role of VDR and DBP polymorphisms in cancer development.

Conclusions:

• Epidemiological and preclinical data support vitamin D's potential as an anticancer agent.
• Further large-scale randomized clinical trials in both healthy individuals and cancer patients are necessary to establish definitive conclusions.
• Long-term effects of high-dose vitamin D, supplementation duration, and baseline levels require investigation.